Found: 6
Select item for more details and to access through your institution.
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
- Published in:
- Translational Psychiatry, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41398-019-0553-z
- By:
- Publication type:
- Article
FHH Quick App Review: How Can a Quality Review Process Assist Primary Care Providers in Choosing a Family Health History App for Patient Care?
- Published in:
- Genes, 2022, v. 13, n. 8, p. 1407, doi. 10.3390/genes13081407
- By:
- Publication type:
- Article
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
- Published in:
- Translational Psychiatry, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41398-023-02557-5
- By:
- Publication type:
- Article
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery‐Åsberg Depression Rating Scale.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 10, p. 1425, doi. 10.1002/psp4.13018
- By:
- Publication type:
- Article
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice